Melanoma Studies

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients (MAVIS)

Investigator:  Bill G Schmidt, MD

Status: Recruiting

Phase: III

Sponsor: Polynoma LLC

Contact: Jennifer Montgomery, 541-706-6590 or jrobinson@bmctotalcare.com

Location: Bend, Oregon (Central Oregon)

Purpose: The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients who have undergone surgery.

Inclusion Criteria:

• Histologically confirmed Stage IIb, IIc, III melanoma
• Surgical resection within 90 days of first dosing
• Persons with positive sentinel nodes must have a complete lymphadenectomy
• ECOG performance status 0 or 1

Exclusion Criteria:

• Any prior melanoma treatment other than surgery or regional irradiation
• Diagnosis of non-cutaneous melanoma or melanoma with unknown primary origin
• Use of biologic response modifiers within 60 days of first dosing
• Subjects with history of other malignancy within past 5 years (with exceptions)

See this trial at ClinicalTrials.gov

DecisionDX-Melanoma 31-Gene Expression Profile Clinical Impact Study

Status: Recruiting

Phase: IV

Sponsor: Castle Biosciences, Inc.

Contact: Jennifer Montgomery, 541-706-6590 or jmontgomery@bmctotalcare.com

Purpose:

To evaluate the impact of the 31-gene expression profile (Decision-DX™ – Melanoma) results on physician recommendations regarding follow-up, surveillance and therapeutic management for cutaneous melanoma stage I-III patients.

Inclusion Criteria:

• Newly diagnosed stage I-III cutaneous melanoma patients for whom the physician has determined the DecisionDX-Melanoma test to be clinically appropriate and medically necessary for management guidance
• Male and female patients ≥18 years of age
• Patient must be able to speak and read English and be able to give informed consent

Exclusion Criteria:

• Employees and family members of Investigator
• Patients unable to provide informed consent
• Patients for whom clinical testing with DecisionDX Melanoma is not appropriate (i.e., in situ melanoma, stage IV disease at time of diagnosis, any other non-eligible clinical population)

For general inquiries, please contact the BMC Research Department at research@bmctotalcare.com or 877-692-8338.

Back to Clinical Research

Print